# US 2008/0188513 A1 · 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188513 A1
- Document ID: US20080188513A1
- Status: Published application
- Kind: A1
- Application number: 11/813,005
- Filed: 2005-12-28
- Published: 2008-08-07
- Earliest claimed: 2004-12-30
- Assignees: taked Pharmaceutical Company Limited
- Inventors: Raymond D. Skwierczynski; Myles L. Brostrom; Tai T. Tran; Joel R. Jacobson
- Web page: https://patentgrep.com/patent/US20080188513A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides methanesulfonate and ethanesulfonate salts of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine, pharmaceutical compositions containing the salts, methods of making, and methods of use.

## Claims

### Claim 1

A salt selected from the group consisting of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate, or a solvate or hydrate thereof.

### Claim 2 (depends on 1)

The salt of claim 1, wherein the salt is 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate, or a solvate or hydrate thereof.

### Claim 3 (depends on 1)

The salt of claim 1, wherein the salt is 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate, or a solvate or hydrate thereof.

### Claim 4 (depends on 1)

The salt of claim 1 in dissolved form.

### Claim 5 (depends on 1)

The salt of claim 1 in solid form.

### Claim 6 (depends on 5)

The salt of claim 5 in crystalline form.

### Claim 7 (depends on 5)

The salt of claim 5 in amorphous form.

### Claim 8 (depends on 5)

The salt of claim 5 in solvated form.

### Claim 9 (depends on 5)

The salt of claim 5 in hydrate form.

### Claim 10 (depends on 9)

The salt of claim 9, in the form of a monohydrate.

### Claim 11

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the salt of any preceding claim.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11 wherein the pharmaceutically acceptable carrier comprises water.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of treating a neoplastic disease in an animal, the method comprising administering a therapeutically effective amount of a salt of any one of claims 1 through 10, or a pharmaceutical composition of claim 11 or claim 12 to the animal.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of treating a viral disease in an animal, the method comprising administering a therapeutically effective amount of a salt of any one of claims 1 through 10, or a pharmaceutical composition of claim 11 or claim 12 to the animal.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of inducing cytokine biosynthesis in an animal, the method comprising administering an effective amount of a salt of any one of claims 1 through 10, or a pharmaceutical composition of claim 11 or claim 12 to the animal.

### Claim 16 (depends on 13)

The method of claim 13, wherein the neoplastic disease is located in the cervix.

### Claim 17 (depends on 14)

The method of claim 14, wherein the viral disease comprises human papilloma virus located in the cervix.

### Claim 18

A method for preparing 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate, the method comprising:
combining 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine free base with ethanesulfonic acid and a carrier to form a mixture, wherein the carrier comprises an organic liquid and optionally water; and
allowing the components of the mixture to react under sufficient conditions to form 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate.

### Claim 19 (depends on 18)

The method of claim 18 further comprising heating the free base, ethanesulfonic acid, and/or the carrier prior to combining them, and/or heating the mixture thereof.

### Claim 20 (depends on 18, 19)

The method of claim 18 or claim 19 further comprising forming a precipitate of the 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate in the mixture.

### Claim 21 (depends on 20)

The method of claim 20 wherein forming a precipitate comprises cooling the mixture to form a precipitate.

### Claim 22 (depends on 21)

The method of claim 21 wherein cooling occurs at a rate less than 2.0° C. per minute.

### Claim 23 (depends on 18, 19, 20, 21, 22)

The method of any one of claims 18 through 22 wherein the carrier comprises at least two moles of water per mole of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine free base present.

### Claim 24 (depends on 20)

The method of claim 20 further comprising:
optionally adding an additional organic liquid to the mixture comprising the precipitate;
separating at least a portion of the precipitate from at least a portion of the mixture;
washing the precipitate; and
at least partially drying the precipitate.

### Claim 25 (depends on 3)

The salt of claim 3 in crystalline form and having an X-ray powder diffraction pattern with peaks at 8.51 degrees two-theta, 14.12 degrees two-theta, 16.80 degrees two-theta, 17.88 degrees two-theta, 21.43 degrees two-theta, 23.24 degrees two-theta, and 29.16 degrees two-theta, wherein each of these values is ±0.15 degree two-theta.

### Claim 26 (depends on 25)

The salt of claim 25 having an X-ray powder diffraction pattern with peaks at 7.15 degrees two-theta, 8.51 degrees two-theta, 14.12 degrees two-theta, 16.80 degrees two-theta, 17.88 degrees two-theta, 18.49 degrees two-theta, 18.88 degrees two-theta, 21.04 degrees two-theta, 21.43 degrees two-theta, 23.24 degrees two-theta, 25.40 degrees two-theta, 27.92 degrees two-theta, 28.77 degrees two-theta, and 29.16 degrees two-theta, wherein each of these values is ±0.15 degree two-theta.

### Claim 27 (depends on 26)

The salt of claim 26 having an X-ray powder diffraction pattern with peaks at 7.15 degrees two-theta, 7.55 degrees two-theta, 8.51 degrees two-theta, 11.83 degrees two-theta, 13.65 degrees two-theta, 14.12 degrees two-theta, 14.87 degrees two-theta, 16.80 degrees two-theta, 17.88 degrees two-theta, 18.49 degrees two-theta, 18.88 degrees two-theta, 19.92 degrees two-theta, 20.24 degrees two-theta, 21.04 degrees two-theta, 21.43 degrees two-theta, 22.24 degrees two-theta, 23.24 degrees two-theta, 24.64 degrees two-theta, 25.40 degrees two-theta, 25.71 degrees two-theta, 27.20 degrees two-theta, 27.92 degrees two-theta, 28.77 degrees two-theta, 29.16 degrees two-theta, 30.94 degrees two-theta, 31.29 degrees two-theta, 32.76 degrees two-theta, 33.56 degrees two-theta, 34.04 degrees two-theta, 34.88 degrees two-theta, and 35.40 degrees two-theta, wherein each of these values is ±0.15 degree two-theta.

### Claim 28 (depends on 3)

The salt of claim 3 having a unit cell with the following crystal interplanar spacings: about 10.38 Angstroms, about 6.27 Angstroms, about 5.27 Angstroms, about 4.96 Angstroms, about 4.14 Angstroms, about 3.82 Angstroms, and about 3.06 Angstroms.

### Claim 29 (depends on 3)

The salt of claim 3 characterized by:
having an X-ray powder diffraction pattern with peaks at 7.15 degrees two-theta, 8.51 degrees two-theta, 14.12 degrees two-theta, 16.80 degrees two-theta, 17.88 degrees two-theta, 18.49 degrees two-theta, 18.88 degrees two-theta, 21.04 degrees two-theta, 21.43 degrees two-theta, 23.24 degrees two-theta, 25.40 degrees two-theta, 27.92 degrees two-theta, 28.77 degrees two-theta, and 29.16 degrees two-theta, wherein each of these values is +0.15 degree two-theta; and
a weight loss of 4.5% to 5.5% over a temperature range of 60° C. to 80° C. as measured by thermogravimetric analysis.

### Claim 30

1-(2-Methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate having an X-ray powder diffraction pattern substantially as depicted in FIG. 1.

### Claim 31

A method for preparing 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate, the method comprising:
combining 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine free base with methanesulfonic acid and a carrier to form a mixture, wherein the carrier comprises an organic liquid and optionally water; and
allowing the components of the mixture to react under sufficient conditions to form 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate.

### Claim 32 (depends on 31)

The method of claim 31 further comprising heating the free base, methanesulfonic acid, and/or the carrier prior to combining them, and/or heating the mixture thereof.

### Claim 33 (depends on 31, 32)

The method of claim 31 or claim 32 further comprising forming a precipitate of the 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate in the mixture.

### Claim 34 (depends on 33)

The method of claim 33 wherein forming a precipitate comprises cooling the mixture to form a precipitate.

### Claim 35 (depends on 31, 32, 33, 34)

The method of any one of claims 31 through 34 wherein the carrier comprises at least two moles of water per mole of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine free base present.

### Claim 36 (depends on 33)

The method of claim 33 further comprising:
optionally adding an additional organic liquid to the mixture comprising the precipitate;
separating at least a portion of the precipitate from at least a portion of the mixture;
washing the precipitate; and
at least partially drying the precipitate.

### Claim 37

A method of treating high risk cervical HPV infection by applying to the cervix a topical formulation comprising dissolved salt 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate or 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate.
